Highly galactosylated anti-TNF-α antibodies and uses thereof
First Claim
Patent Images
1. A composition, comprising:
- a population of antibodies,wherein the antibodies in the population of antibodies are anti-TNF-alpha antibodies produced in mammary gland epithelial cells of a transgenic non-human mammal;
wherein the level of galactosylation of the antibodies in the population of antibodies comprises at least 5% mono-galactosylated N-glycans or at least 10% bi-galactosylated N-glycans;
wherein the level of fucosylation of the antibodies in the population of antibodies is at least 30%; and
wherein the antibodies in the population of antibodies comprise a heavy chain comprising SEQ ID NO;
1 and a light chain comprising SEQ ID NO;
2.
1 Assignment
0 Petitions
Accused Products
Abstract
In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.
-
Citations
20 Claims
-
1. A composition, comprising:
-
a population of antibodies, wherein the antibodies in the population of antibodies are anti-TNF-alpha antibodies produced in mammary gland epithelial cells of a transgenic non-human mammal; wherein the level of galactosylation of the antibodies in the population of antibodies comprises at least 5% mono-galactosylated N-glycans or at least 10% bi-galactosylated N-glycans; wherein the level of fucosylation of the antibodies in the population of antibodies is at least 30%; and wherein the antibodies in the population of antibodies comprise a heavy chain comprising SEQ ID NO;
1 and a light chain comprising SEQ ID NO;
2. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A composition, comprising:
-
a population of antibodies, wherein the antibodies in the population of antibodies are anti-TNF-alpha antibodies produced in mammary gland epithelial cells of a transgenic non-human mammal; wherein at least 30% of the antibodies in the population of antibodies contain at least one oligomannose; wherein the level of fucosylation of the antibodies in the population of antibodies is at least 30%; and wherein the antibodies in the population of antibodies comprise a heavy chain comprising SEQ ID NO;
1 and a light chain comprising SEQ ID NO;
2. - View Dependent Claims (16, 17, 18, 19, 20)
-
Specification